Sub-Visible Particles (SVP)

Sub-visible particles (SVPs) are particles present in parenteral drug products that are not visible to the naked eye, typically ranging in size from 1 to 100 micrometers (µm). They can be composed of aggregated protein, or they can be foreign matter such as silicone oil droplets or glass flakes. Proteinaceous SVPs are particularly concerning because they can elicit immune responses. Quantitation and control of SVPs are critical indicators of product stability and manufacturing process consistency. While meeting compendial limits is mandatory, the true goal is to understand and minimize the particle population through robust formulation, process, and packaging design, thereby ensuring patient safety and product quality.

• Distinguishing Particle Types: The standard release method, Light Obscuration, cannot distinguish between particles of different origins (e.g., protein vs. silicone oil). This requires the use of orthogonal methods like Flow Imaging to understand the nature of the particles.
• Product-Specific Interferences: Highly concentrated or viscous products can be difficult to analyze accurately by Light Obscuration, requiring specific method development for dilution and sample handling. AAV products can also present unique challenges due to their inherent particulate nature.
• Sampling and Handling: The analysis of SVPs is highly sensitive to handling errors. The introduction of air bubbles, accidental agitation, or contamination from sample containers can easily lead to inaccurate and artificially high results.

• Early Development: A qualified method is used to characterize particle levels in early clinical batches. The focus is on understanding the product's particulate profile and ensuring it is well within pharmacopeial limits.
• Mid-Development: The consistency of the SVP profile is demonstrated. Flow Imaging is used to understand the nature of the particles and the impact of process changes or container/closure systems.
• Late-Stage / BLA Submission: A fully validated Light Obscuration method is required for release testing. The product must meet the compendial limits defined in USP 〈788〉. Data on the characterization of particles, especially in the 2-10 µm range, is expected.

• Patient Risk: The primary risk is immunogenicity. Proteinaceous particles, particularly in the 2-10 µm size range, are known to be potent activators of the immune system and can lead to the formation of anti-drug antibodies (ADAs). This can neutralize the drug's efficacy and, in some cases, cause serious adverse events.
• Manufacturing Risk: High SVP counts indicate a product or process instability. This could be due to issues with the formulation, stress during manufacturing (e.g., pumping, filtration), or an incompatibility with the primary container (e.g., shedding of silicone oil from syringes), leading to batch investigations and rejections.

AAV Gene Therapy: 

The inherent nature of AAV products means that the "particles" being measured can be monomeric or aggregated viral vectors. The challenge is to distinguish between the intrinsic and extrinsic particle populations. AAV formulations are also frequently packaged in pre-filled syringes, making silicone oil a common extrinsic particle that must be monitored.

An increase in SVPs is a direct measure of vector Aggregation and a loss of Purity. This physical instability often correlates with a loss of infectivity and therefore a decrease in Potency. It is the macroscopic consequence of the issues measured by the Appearance test.

Monoclonal Antibodies (mAbs)

For mAbs, the vast majority of product-related SVPs are protein aggregates. High-concentration formulations (>100 mg/mL) are especially susceptible to forming particles due to increased protein-protein interactions and viscosity.

SVP formation is a direct result of physical instability and is a key measure of Aggregation. The formulation's pH and excipients are specifically designed to minimize particle formation. An increase in SVPs on stability often correlates with a loss of Potency.

Control of sub-visible particles is a major focus of formulation, process development, and packaging selection for all parenteral biologics. While Light Obscuration is the required test for meeting the official pharmacopeial limits (≥10 µm and ≥25 µm), Flow Imaging Microscopy is now a standard and expected tool for characterization. Regulators and industry scientists are increasingly focused on particles in the 2-10 µm range due to their potential for immunogenicity, and companies are expected to monitor and control particles in this range even though formal limits do not yet exist.

• Pharmacopeial Limits (USP <788>): This enforceable chapter sets the standard acceptance criteria for SVPs in injections. For small volume parenterals (<100 mL), the limits are:
  • Not more than 6000 particles per container equal to or greater than 10 µm.
  • Not more than 600 particles per container equal to or greater than 25 µm.
• Characterization (USP <1788>): This informational chapter provides details on various methods for analyzing SVPs, including Flow Imaging, and discusses best practices for their characterization.
• Impurity Control (ICH Q6B): Particulate matter is considered a product-related impurity (aggregates) or a contaminant, and its control is a required part of the product's specification.